Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879419 | 0.88 | AR (0.62) | ARLMNAADORA3GAAMEN1 | |
| SCHEMBL13879433 | 0.86 | AR (0.60) | ARLMNAADORA3GAAMEN1 | |
| SCHEMBL4437165 | 0.80 | LMNA (0.54) | ARLMNAADORA3MEN1KMT2A | |
| SCHEMBL4439021 | 0.80 | LMNA (0.54) | ARLMNAADORA3MEN1KMT2A | |
| SCHEMBL4439842 | 0.80 | LMNA (0.54) | ARLMNAADORA3MEN1KMT2A | |
| SCHEMBL6105903 | 0.76 | LMNA (0.56) | ARLMNAADORA3GAAMEN1 | |
| SCHEMBL6399678 | 0.76 | LMNA (0.56) | ARLMNAADORA3GAAMEN1 | |
| SCHEMBL11581813 | 0.76 | GAA (0.46) | ARLMNAGAAMEN1KMT2A | |
| SCHEMBL6401313 | 0.76 | LMNA (0.56) | ARLMNAADORA3GAAMEN1 | |
| SCHEMBL77736 | 0.76 | LMNA (0.61) | ARLMNAADORA3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445343-B1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES PHARMA IRELAND LTD (IE) | 2021-08-04 | — | — | EP | disclosed |
| US-20200375904-A1 | METHOD FOR MANUFACTURING DRUG-CONTAINING PARTICLES | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-12-03 | — | — | US | disclosed |
| US-10723728-B2 | Prodrugs of Nh-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-07-28 | — | — | US | disclosed |
| US-10428058-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-10-01 | — | — | US | disclosed |
| US-20190284181-A9 | PRODRUGS OF NH-ACIDIC COMPOUNDS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-09-19 | — | — | US | disclosed |
| US-20190031648-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES PHARMA IRELAND LTD (IE) | 2019-01-31 | — | — | US | disclosed |
| EP-2585066-B1 | PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES | ALKERMES PHARMA IRELAND LTD (IE) | 2018-09-26 | — | — | EP | disclosed |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-08-07 | — | — | US | disclosed |
| US-20170196848-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | ALKERMES PHARMA IRELAND LTD (IE) | 2017-07-13 | — | — | US | disclosed |
| US-9585965-B2 | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-03-07 | — | — | US | disclosed |
| EP-2585066-A2 | PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES | Alkermes Pharma Ireland Limited (IE) | 2013-05-01 | — | — | EP | disclosed |
| EP-2445343-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | Alkermes, Inc. (US) | 2012-05-02 | — | — | EP | disclosed |
| WO-2011163594-A2 | PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES | ALKERMES, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. | 2011-01-06 | — | — | US | disclosed |
| WO-2010151711-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| EP-1988885-A2 | COMBINATION OF ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007092469-A2 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| EP-1596844-A2 | USE OF SODIUM CHANNEL MODULATORS FOR TREATING GASTROINTESTINAL TRACT DISORDERS | Dynogen Pharmaceuticals Inc. (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004066987-A2 | USE OF SODIUM CHANNEL MODULATORS FOR TREATING GASTROINTESTINAL TRACT DISORDERS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| WO-1996020701-A1 | APOPTOSIS-MODULATING COMPOSITION COMPRISING A FACTOR AFFECTING THE INTRACELLULAR RATE OF METHIONAL OR MALONDIALDEHYDE | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1996-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031648-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | AR 4497/4885LMNA 2642/4885ADORA3 1660/4885 |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | SI, NAAA, NIT2 | AR 4497/4885LMNA 2642/4885ADORA3 1660/4885 |
| US-20190284181-A9 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | AR 4497/4885LMNA 2642/4885ADORA3 1660/4885 |
| US-10428058-B2 | Prodrugs of NH-acidic compounds | SI, NAAA, NIT2 | AR 4497/4885LMNA 2642/4885ADORA3 1660/4885 |
| US-20170196848-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | PHPT1, SI, CA6 | AR 4028/4885LMNA 2841/4885ADORA3 1272/4885 |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | AR 4497/4885LMNA 2642/4885ADORA3 1660/4885 |
| US-10723728-B2 | Prodrugs of Nh-acidic compounds | SI, NAAA, NIT2 | AR 4497/4885LMNA 2642/4885ADORA3 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.